Pharma Understands Phase One Data – But Does the Market?
Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.
Published | 2 min
read
Stay informed
Get the latest insights and news from RBC Capital Markets delivered to your inbox.